Structured page family:Cost guide

Ziconotide Cost Guide: Insurance, Cash Pay, and Savings

In the United States, Ziconotide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.

Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Prialt pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Ziconotide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.

Price Breakdown

List price (monthly)
~$2,500-$3,500/month (drug only)
Average wholesale price
~$2,300-$3,300/month
Pharmacy acquisition estimate
~$2,100-$3,000/month
Typical negotiated rate
~$1,800-$2,500/month
Price per dose
~$85 per 100 mcg vial; ~$425 per 500 mcg vial
Annual cost at list price
~$30,000-$42,000 (drug only; pump and procedure costs additional)

Pharmacy Price Comparison

PharmacyPrice RangeNotes
Specialty pharmacy$2,300-$3,500/monthRequired

Insurance Coverage Landscape

Commercial plans
~70-80% for refractory pain
Medicare Part D
May be Part B (pump/device)
Medicaid
Case-by-case; requires specialist attestation
VA coverage
Available through pain management
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; often requires medical necessity review

Prior Authorization Guide

Required Documentation
  • Severe chronic pain diagnosis
  • Failure of oral/transdermal opioids and adjuvants
  • Pain specialist attestation
  • Intrathecal therapy candidate evaluation
Common Denial Reasons
  • Not refractory enough
  • No specialist involvement
  • Plan requires less invasive alternatives first
  • Psychiatric contraindications
Appeal Template Points
  • Refractory to all conventional therapy
  • Pain specialist evaluation attached
  • Intrathecal therapy appropriate
  • No respiratory depression risk (advantage over opioids)
  • Improves quality of life
Expected timeline: 2-4 weeks

Savings Programs and Patient Assistance

Manufacturer PAP
manufacturer
Eligibility: Uninsured/underinsured
Savings: May provide at reduced cost
Income limit: Case-by-case
Enrollment: complex
Limited program

Generic and Biosimilar Status

No generic currently available
Expected: No generic expected

Cost by Dose

Dose/RegimenMonthlyAnnual
0.1-0.5 mcg/hour$2,500-$3,000$30,000-$36,000
0.5-0.8 mcg/hour$3,000-$3,500$36,000-$42,000

Annual Cost Projection

Year 1
$40,000-$60,000 (includes pump implant)
Year 2
$30,000-$45,000 (maintenance)
Year 3
$30,000-$45,000
Assumptions
  • Implant cost year 1
  • Pump replacement every 5-7 years

Cost-Saving Strategies

  • 1.Pump implantation and refills are major costs beyond drug — negotiate bundled pricing with center
  • 2.Document exhaustive failed therapies for prior auth
  • 3.Consider intrathecal morphine combination if ziconotide alone insufficient (may reduce doses)
  • 4.VA and academic pain centers may offer more favorable pricing

International Price Comparison

CountryPrice RangeNotes
UKNHS specialized pain serviceLimited availability

Need help comparing ziconotide paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a ziconotide provider
Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.

Ziconotide Cost FAQ

Sources

  1. 1. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    J Pain Symptom Manage • 2006
    Claim type: clinical
    View source →
  2. 2. FDA Information on Ziconotide
    FDA • 2026
    Claim type: regulatory
    View source →

This content is for informational purposes only and does not constitute medical advice.